Back to top
more

Eyenovia (EYEN)

(Delayed Data from NSDQ)

$1.07 USD

1.07
1,428,261

-0.10 (-8.55%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $1.08 +0.01 (0.93%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CannTrust (CTST) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.

What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?

by Zacks Equity Research

Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.

Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.

EPAM Systems (EPAM) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

EPAM Systems' (EPAM) third-quarter results are likely to reflect broad-based demand for its digital solutions.

TiVo (TIVO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

TiVo's (TIVO) third-quarter results are likely to reflect higher licensing agreement wins.

Factors to Consider Ahead of Cutera's (CUTR) Q3 Earnings

by Zacks Equity Research

Cutera (CUTR) third-quarter results are likely to reflect benefits from the incremental adoption of truSculpt iD and 3D products.

Expedia Group's (EXPE) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Expedia Group (EXPE) third-quarter results are expected to reflect strength across Core OTA, Vrbo and Egencia. However, weakness in trivago is likely to have impacted its performance negatively.

Factors Setting the Tone for Square's (SQ) Earnings in Q3

by Zacks Equity Research

Square's (SQ) third-quarter results are likely to reflect its strength across sellers.

Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?

by Zacks Equity Research

Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.

Eyenovia Initiates Phase III Study for Mydriasis Candidate

by Zacks Equity Research

Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.

Eyenovia Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Eyenovia has been struggling lately, but the selling pressure may be coming to an end soon.

    Eyenovia Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    Eyenovia has been struggling lately, but the selling pressure may be coming to an end soon.

      Eyenovia, Inc. (EYEN) Sees Hammer Chart Pattern: Time to Buy?

      by Zacks Equity Research

      Eyenovia, Inc. (EYEN) Sees Hammer Chart Pattern: Time to Buy?